EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review

Dani Ran Castillo iD, Daniel Park, Won Jin Jeon iD, Bowon Joung, Jae Lee, Chieh Yang iD, Bryan Pham, Christopher Hino iD, Esther Chong iD, Andrea Shields, Anthony Nguyen, Joel Brothers und 3 weitere

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241210207 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Dani Ran Castillo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) characterized by a hallmark translocation of t (11; 14). CD10 negativity has been used to differentiate MCL from other NHL types; however, recently, there has been an increase in the number of reported cases of CD10-positive MCL. This warrants further investigation into this rarer immunophenotype and its clinical significance. BCL6, which is a master transcription factor for the regulation of cell proliferation and key oncogene in B cell lymphomagenesis, has been reported to have co-expression with CD10 in MCL. The clinical significance of this aberrant antigen expression remains unknown. We conducted a systematic review by searching four databases and selected five retrospective analyses and five case series. Two survival analyses were conducted to determine if BCL6 positivity conferred a survival difference: 1. BCL6+ vs. BCL6− MCL. 2. BCL6+/CD10+ vs. BCL6−/CD10+ MCL. Correlation analysis was conducted to determine if BCL6 positivity correlated with the Ki67 proliferation index (PI). Overall survival (OS) rates were performed by the Kaplan–Meier method and log-rank test. Our analyses revealed that BCL6+ MCL had significantly shorter overall survival (median OS: 14 months vs. 43 months; p = 0.01), BCL6+/CD10+ MCL had an inferior outcome vs. BCL6+/CD10− MCL (median OS: 20 months vs. 55 months p = 0.1828), BCL6+ MCL had significantly higher percentages of Ki67% (Ki67% difference: 24.29; p = 0.0094), and BCL6 positivity had a positive correlation with CD10+ status with an odds ratio 5.11 (2.49, 10.46; p = 0.0000286). Our analysis showed that BCL6 expression is correlated with CD10 positivity in MCL, and BCL6 expression demonstrated an inferior overall survival. The higher Ki67 PI in BCL6+ MCL compared to BCL6− MCL further supports the idea that the BCL6+ immunophenotype may have prognostic value in MCL. MCL management should consider incorporating prognostic scoring systems adjusted for BCL6 expression. Targeted therapies against BCL6 may offer potential therapeutic options for managing MCL with aberrant immunophenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellHumansAdultNeprilysinProto-Oncogene Proteins c-bcl-6Retrospective StudiesPrognosisKi-67 Antigen

Stichwörter der Autor:innen

BCL6CD10aberrant MCL immunophenotypeoverall survival

Substanzen

NeprilysinProto-Oncogene Proteins c-bcl-6Ki-67 AntigenBCL6 protein, human

Autor:innen und Institutionen

  • Department of Oncology/Hematology, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
  • Department of Internal Medicine, School of Medicine, University of California San Francisco-Fresno, Fresno, CA 93701, USA.
  • Department of Internal Medicine, School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
  • School of Medicine, Loma Linda University, Loma Linda, CA 92354, USA.
  • Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA 92521, USA.
  • Department of Pathology, Loma Linda University, Loma Linda, CA 92354, USA.

ORCID-Profile: Dani Ran Castillo, Won Jin Jeon, Chieh Yang, Christopher Hino, Esther Chong

Zitieren

APA

Castillo, D. R., Park, D., Jeon, W. J., Joung, B., Lee, J., Yang, C., Pham, B., Hino, C., Chong, E., Shields, A., Nguyen, A., Brothers, J., Liu, Y., Zhang, K. K., & Cao, H. (2023). Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210207

Vancouver

Castillo DR, Park D, Jeon WJ, Joung B, Lee J, Yang C, et al. Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210207

BibTeX
@article{Castillo2023,
  author = {Castillo, Dani Ran and Park, Daniel and Jeon, Won Jin and Joung, Bowon and Lee, Jae and Yang, Chieh and Pham, Bryan and Hino, Christopher and Chong, Esther and Shields, Andrea and Nguyen, Anthony and Brothers, Joel and Liu, Yan and Zhang, Ke K and Cao, Huynh},
  title = {Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241210207}
}
Kostenlos starten →